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The development of mature adipocytes from pre-adipocytes is a highly regulated process. CD24 is a
glycophosphatidylinositol-linked cell surface receptor that has been identified as a critical cell surface marker for
identifying pre-adipocytes that are able to reconstitute white adipose tissue (WAT) in vivo. Here, we examined the role
and regulation of CD24 during adipogenesis in vitro. We found that CD24 mRNA and protein expression is upregulated
early during adipogenesis in the 3T3-L1 pre-adipocytes and in murine primary pre-adipocytes isolated from
subcutaneous and visceral WAT, followed by downregulation in mature adipocytes. CD24 mRNA expression was found
to be dependent on increased transcription due to increased promoter activity in response to activation of a pre-
existing transcriptional regulator. Furthermore, either intracellular cAMP or dexamethasone were sufficient to increase
expression in pre-adipocytes, while both additively increased CD24 expression. Preventing the increase in CD24
expression, by siRNA-mediated knock-down, resulted in fewer mature lipid-laden adipocytes and decreased expression
of mature adipogenic genes. Therefore, conditions experienced during adipogenesis in vitro are sufficient to increase
CD24 expression, which is necessary for differentiation. Overall, we conclude that the dynamic upregulation of CD24
actively promotes adipogenesis in vitro.
Background
Obesity is caused by a positive imbalance in caloric intake vs.
expenditure and is exacerbated by environmental and genetic fac-
tors.1 White adipose tissue (WAT) plays critical roles in energy
balance via storage of excess energy as triglycerides, and in hor-
monal regulation via secretion of appetite regulating hormones
such as adiponectin and leptin.2 WAT can increase in size
throughout life due to a combination of increased cell size
(hypertrophy) and increased cell number (hyperplasia).2 WAT is
composed of multiple cell types including adipocytes, pre-adipo-
cytes, macrophages, lymphocytes, vascular cells, epithelial cells
and adipose-derived stem cells (ADSC). WAT is located in mul-
tiple depots, including subcutaneous depots beneath the skin and
visceral depots surrounding internal organs.
Differentiation of ADSCs or pre-adipocytes into mature lipid-
laden adipocytes is a multi-stage process. Pre-adipocytes undergo
clonal expansion followed by activation of transcriptional cas-
cades that activate ‘master regulators’ CCAAT enhancer binding
protein (C/EBP) a and peroxisome proliferator-activated recep-
tor g (PPARg).3-6 In addition, different WAT depots show vary-
ing degrees of differentiation potential.2 While the later stages of
adipogenesis have been well characterized, the very early molecu-
lar events defining pre-adipocyte lineage commitment, as well as
the precise identity of the adipocyte progenitors are less well
understood.
Mature adipocytes arise from multi-potent mesenchymal stem
cells that can differentiate into osteoblasts, myoblasts, and adipo-
cytes.7 Cells committed to the adipocyte lineage arise from the
perivascular region within WAT.8 These pre-adipocytes express
specific transcription factors, such as ZFP423, and other stem
cell associated markers including SCA1 and CD34.7 However,
the precise molecular mechanisms that promote early pre-adipo-
cyte lineage commitment are still under intense investigation.
Adipocyte differentiation is regulated by both pro-adipogenic
and anti-adipogenic intracellular transcriptional regulators. For
example, the transcription factor kruppel-like factor (KLF) 4 acts
early during adipogenesis, along with the Krox20 transcription
factor, to promote the expression of C/EBPb and C/EBPd.9
PPARg expression is then induced by the activity of C/EBPb
and C/EBPd, along with KLF6, and can be modified by other
regulators.3-6,10 Similarly, C/EBPa expression is induced by the
activity of C/EBPb and C/EBPd, along with KLF5.3-6,10
C/EBPa and PPARg expression are both necessary and sufficient
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to promote adipogenesis,3-6 however, both the increase in pro-
adipogenic gene expression and a decrease in anti-adipogenic
gene expression are necessary for successful adipogenesis. For
example, pre-adipocyte factor 1 (PREF1, also known as DLK1)
is an inhibitor of adipocyte differentiation that is highly expressed
in pre-adipocytes, but not detected in mature adipocytes.11
PREF1 downregulation by the KLF6 transcription factor is a crit-
ical event to allow adipogenesis.12
Adipogenesis is modeled successfully in vitro using either
immortalized pre-adipocyte cell lines, such as 3T3-L1, or pri-
mary cells isolated from the WAT derived stromal vascular frac-
tion (SVF).2,13 Addition of supraphysiological levels of 3-
isobutyl-1-methylxanthine (IBMX), dexamethasone (Dex) and
insulin stimulates differentiation and highlights the importance
of the cAMP, glucocorticoid and insulin/insulin-like growth fac-
tor-1 (IGF-1) signaling pathways in adipocyte development.6
IBMX is a cyclic nucleotide phosphodiesterase inhibitor that dra-
matically increases intracellular cAMP levels.14 The cAMP signal
then activates C/EBPb gene expression via the CREB transcrip-
tion factor.13 Dex is a synthetic glucocorticoid that induces gene
expression,15 and has been proposed to prime pre-adipocytes for
differentiation along the adipogenesis pathway.16 Insulin acti-
vates the IGF-1 signaling pathway by recruiting and phosphory-
lating insulin receptor substrate proteins. This leads to the
activation of the phosphatidylinositol-3-kinase pathway, among
others.17 This cocktail of factors is essential and sufficient to
direct adipogenic differentiation in vitro in both pre-adipocyte
cell lines and primary pre-adipocytes.
Previously, a subpopulation of adipocyte progenitor cells was
identified with the expression of the cell surface molecule CD24
being critically important for reconstitution of WAT function in
vivo but apparently dispensable for adipogenesis in vitro.18 More
recently, it was shown that pre-adipocytes lose CD24 expression
as they commit to the adipocyte lineage.19 CD24 is a heavily gly-
cosylated glycophosphatidylinositol (GPI)-linked cell surface
receptor found on a variety of cell types including cancer cells,
precursor B lymphocytes, neurons, epithelial cells, macrophages
and pre-adipocytes, among others.20 In general, it is highly
expressed on progenitor cells and to a lesser extent on terminally
differentiated cells. CD24 can regulate cell survival in a cell- type
dependent manner in B lymphocytes, cancer cells, and neurons,
as well as regulating activation of T cells and dendritic cells. It is
overexpressed in many types of cancers, causing cancer cell
growth, proliferation and metastasis21; yet CD24 activation
induces apoptosis in precursor B lymphocytes.22 The molecular
role of CD24 during pre-adipocyte commitment and adipogene-
sis is not known.
We hypothesized that if CD24 were an important factor in
regulating adipogenesis, then its expression would be actively reg-
ulated during differentiation in vitro. Therefore, we analyzed
CD24 expression in 3T3-L1 pre-adipocytes and primary pre-adi-
pocytes from 2 different depots to show that CD24 expression is
dramatically regulated during the early phases of adipogenesis.
We show that this regulation depends on cAMP and glucocorti-
coid signaling. Moreover, we find that inhibiting CD24 expres-
sion during early commitment and differentiation using siRNA
significantly reduces adipocyte development and mature adipo-
cyte gene expression. Thus, the dynamic increase in CD24
expression during early adipogenesis is an important functional
contributor to adipocyte differentiation in vitro.
Results
CD24 mRNA and protein levels increase at initiation
of adipogenesis in vitro
To determine at which stage in adipogenesis CD24 may
contribute, we first assessed if the expression level of CD24
changed over the course of adipogenesis. In order to analyze
adipogenic-induced changes in gene expression in as many dis-
crete stages as possible, we chose to induce adipogenesis by add-
ing the IBMX/Dex initiation solution 48 h prior to addition of
insulin, rather than in one cocktail. We then analyzed the
mRNA levels of CD24 and other genes known to be important
in adipogenesis in 3T3-L1 pre-adipocyte cell line by quantita-
tive RT-PCR (RT-qPCR) (Fig. 1). We found that the expres-
sion of the pre-adipocyte associated gene Pref1 decreased with
adipocyte differentiation even though the decrease was not sta-
tistically significant by 1-way ANOVA analysis. As expected,
Pparg, Cebpa and adiponectin (Adipoq) expression increased
significantly over the course of adipogenesis with the highest
expression seen at maturity, demonstrating successful adipocyte
development at the transcript level. Strikingly, CD24 expression
significantly increased 6 h after adipogenesis was initiated by
IBMX C Dex addition, followed by a return to baseline levels
48 h later, coincident with addition of insulin, a stage termed
progression.
To determine if this dynamic change in CD24 mRNA expres-
sion also occurred in primary pre-adipocytes undergoing adipo-
genesis, cells isolated from the SVF of visceral epididymal (eSVF)
or subcutaneous inguinal WAT (siSVF) were induced to undergo
adipogenesis in culture (Fig. 2). We found that Pref1 expression
decreased upon differentiation to mature adipocytes in the eSVF
as expected but showed increased expression at progression and
maturity cells from siSVF. In the case of Pparg, both depots had
increased expression as cells matured, but siSVF had an earlier
and higher response than eSVF cells. Similarly, adiponectin
increased by maturity in cells from both depots with an earlier
and more profound increase in siSVF. Cebpa expression
increased significantly at maturity in siSVF but we did not
observe any change in Cebpa from eSVF in the timeframe exam-
ined (Fig. 2).
The expression of CD24 increased dynamically over the
course of adipogenesis in cells from both depots (Fig. 2). Cells
from the eSVF had increased expression of CD24 on response to
addition of IBMX C Dex (initiation) and this increase persisted
after the replacement of progression media with insulin. By
maturity, the expression returned to levels statistically similar to
confluent cells. There was a more dynamic regulation of CD24
in siSVF with significantly increased expression to a higher mag-
nitude than eSVF in response to IBMX C Dex, followed by a
swift reversal to initial levels at progression and maturity, in a
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manner similar to that seen with the 3T3-L1 pre-adipocytes.
Strikingly, both the increase and decrease in CD24 expression
were more pronounced in pre-adipocytes from siSVF compared
to eSVF.
To determine if changes to CD24 mRNA expression corre-
lated with changes to total protein expression, we examined
CD24 protein expression levels in the 3T3-L1 cells at different
stages of adipogenesis. We found that total CD24 protein levels,
Figure 2. CD24 and adipogenic mRNA expression over the course of adipogenesis in primary cultures from epididymal and inguinal white adipose tissue
depots. The mRNA expression of CD24 and known adipogenic genes were determined from pre-adipocytes isolated from visceral epididymal WAT (eSVF)
or subcutaneous inguinal WAT (siSVF), at the indicated stages of the adipogenesis assay, as described in Figure 1. Expression levels of Pref1, Pparg,
Cebpa, Adiponectin and CD24 were determined by RT-qPCR followed by normalization to the internal control gene Rplp0. Relative expression levels are
shown with respect to levels in confluent cells. Data is shown as log2 transformed mean § s.e.m., n D 8. Different letters indicate a significant difference
at P< 0.05 (upper case: eSVF, lower case: siSVF).
Figure 1. CD24 and adipogenic mRNA expression over the course of adipogenesis in 3T3-L1 pre-adipocytes. The mRNA expression of CD24 and known
adipogenic genes was determined at the indicated stages of the adipogenesis assay (Prol: proliferating pre-adipocytes; Conf: 100% confluent; Init: 6 h
after addition of IBMX C Dex; Prog: 6 h after addition of insulin; Mat: 5 days after addition of insulin). Expression levels of Pref1, Pparg, Cebpa, Adiponec-
tin and CD24 were determined by RT-qPCR followed by normalization to the internal control gene Rplp0. Relative expression levels are shown with
respect to levels in proliferating cells. Data is shown as log2 transformed mean § s.e.m., n D 3-4. Different lower case letters indicate a significant differ-
ence at P< 0.05.
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as determined by western blot, increased 6 h after initiation of
adipogenesis with IBMX C Dex, and remained high for 24 h,
followed by a reduction to baseline after addition of insulin con-
taining progression media 48 h later (Fig. 3A). Thus, changes to
total CD24 protein mirrored the changes in mRNA expression.
Since CD24 is a surface protein, we next analyzed surface
CD24 surface protein expression using flow cytometry where the
mean fluorescent intensity (MFI) at each stage was compared to
a time matched confluent control (Fig. 3B). We found that
the relative level of surface expression increased significantly
in response to 20 h, but not 6 h, of IBMX/Dex treatment,
remained high throughout progression, and decreased by matu-
rity (Fig. 3B and C). Overall, both the increase and decrease in
CD24 surface protein expression was delayed compared to total
protein expression and mRNA expression. However, similar to
mRNA and total protein, the surface expression levels decreased
to control levels by maturity (Fig. 3B and C). We also observed
that there was bimodal expression of CD24 with 80% of conflu-
ent cells clearly positive for CD24 surface expression (Fig. 3B
and C). In response to 20 h of IBMX C Dex treatment, there
was a shift in the population so that there was a normal distribu-
tion with over 90% cells positive for CD24 expression. The
time-matched control also exhibited a shift in population dynam-
ics toward a more uniform distribution of surface CD24 suggest-
ing that culture conditions and time also alter CD24 expression,
albeit in a less dramatic manner. The percentage of CD24-posi-
tive cells remained high (90.7 § 0.6%) throughout maturity
demonstrating the most cells retain CD24 expression once they
acquire it, but at a lower overall level.
To determine if changes to CD24 protein expression also
occurred in primary pre-adipocytes, surface CD24 protein was
analyzed at select stages of adipogenesis in cells from siSVF since
these cells showed a more robust change in CD24 mRNA expres-
sion compared to eSVF. We observed that these cells had a clear
bimodal distribution of CD24 expression with 43 § 5% of cells
CD24-positive at the confluent stage (Fig. 4). There was an ini-
tial decrease in the number of CD24-positive cells with 6 h of
IBMX C Dex treatment, which was followed by a significant
increase in CD24-positive cells and a loss of the 2 distinct popu-
lations at progression (Fig. 4A). By maturity, the majority of the
Figure 3. Total and surface CD24 protein over the course of adipogenesis in 3T3-L1 cells. (A) Total protein expression of CD24 in 3T3-L1 cells was deter-
mined by western blot analysis at the indicated stages of adipogenesis (Conf: 100% confluent; I-6 h: 6 h after addition of IBMX C Dex; I-24 h: 24 h after
IBMX C Dex addition; Prog: 6 h after addition of insulin; Mat: 5 days after addition of insulin). Actin is used the loading control and the location of molec-
ular mass standards (kDa) are indicated on the right. One representative of 3 independent experiments is shown. (B) Surface CD24 protein expression in
3T3-L1 cells was detected by flow cytometry using anti-CD24-APC or isotype-APC staining control at the indicated stages of adipogenesis, as above (I-
20 h: 20 h after IBMX C Dex). All treated samples are compared to a time-matched untreated confluent control. The dashed line indicates the cut-off for
CD24-positive vs. negative cells. One representative experiment is shown. (C) Right panel: The relative surface expression of CD24 was calculated relative
to the time matched control using mean fluorescence intensity. Left panel: The percent CD24-positive cells were calculated at each time point. Data
shown as mean § s.e.m., n D 6-7. Different lower case letters indicate a significant difference at P < 0.05.
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cells had become CD24-negative with an overall shift to a normal
distribution of surface expression (Fig 4A). Similar to the 3T3-L1
cells, both the increase and decrease in CD24 surface expression
was delayed compared to the changes in mRNA. Because of the
limited numbers of SVF cells that were collected, we were unable
to obtain a time-matched confluent control for every stage and so
relative quantitative analysis of surface
expression could not be performed. How-
ever, there did not appear to be an increase
in the expression of CD24 on CD24-posi-
tive cells, rather there was a shift in the
number of low-expressing or CD24-nega-
tive cells to high-expressing cells, and vice
versa.
cAMP and glucocorticoid signaling
cooperate to upregulate CD24 mRNA
expression via transcriptional activation
The dynamic increase in CD24 expres-
sion in pre-adipocytes has never been
described previously, therefore we per-
formed additional characterizations on the
regulation of CD24 mRNA by IBMX C
Dex treatment. To determine which com-
ponents of the initiation media are necessary
to increase CD24 expression we treated cells
with media only, IBMX, Dex or both com-
pounds and CD24 mRNA levels were ana-
lyzed (Fig. 5A). We found that while
treatment with IBMX or Dex significantly
increased CD24 expression, treatment with
both caused an additive increase in CD24
expression. However, based on the statistical
analysis, the induction of IBMX was not sig-
nificantly differently than the induction by
IBMX C Dex, suggesting that IBMX is a
stronger activator than Dex.
We next tested if insulin affected the
induction CD24 expression since adipo-
genesis can be induced if all 3 compounds
are added simultaneously. We found that
addition of insulin to IBMX C Dex treatment did not affect
the IBMX C Dex-mediated increase in CD24 expression
(Fig. 5B). Therefore, while the addition of both IBMX and
Dex is necessary to maximally increase CD24 mRNA levels,
insulin does not contribute to either promoting or limiting the
increase in CD24.
Figure 4. Surface CD24 protein over the course of adipogenesis in primary pre-adipocytes. (A) Surface CD24 protein expression on cells isolated from
siSVF was determined by flow cytometry, at select stages of adipogenesis, using the biotinylated anti-CD24 M1/69 antibody. Streptavidin-FITC (Strep-
FITC) alone is used as the negative control for staining. One representative experiment is shown. (B) The percent of CD24 C cells from each individual
animal (£) and the mean (¡) is indicated, n D 4 sets of cells pooled from 2 mice each. Different lower case letters indicate a significant difference at
P < 0.05.
Figure 5. cAMP and Dex cooperate to increase CD24 mRNA expression in confluent 3T3-L1 pre-
adipocytes. Confluent 3T3-L1 cells were treated for 6 h with 10%FBS/DMEM media alone (con-
trol), dexamethasone (Dex), IBMX, IBMX C Dex (I/D), insulin (Ins), Forskolin or the inactive Forsko-
lin analog (iForskolin), as indicated. (A, B, D) CD24 mRNA expression was determined by RT-qPCR
and normalized to the internal control Rplp0 and calculated relative to levels in control cells. Data
is shown as log2 transformed mean § s.e.m., n D 4. The fold increase of CD24 by Forskolin over
iForskolin is indicated. (C) Intracellular cAMP levels were determined by ELISA. Data shown as
mean § s.e.m., n D 3. nd D not detected in the number of samples indicated in parenthesis. Dif-
ferent lower case letters indicate a significant difference at P < 0.05.
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IBMX treatment increases intracellular cAMP levels14 and
Dex has been shown to inhibit cAMP phosphodiesterase expres-
sion at later time points, further increasing cAMP levels.23 There-
fore, we assessed the change in cAMP levels in response to IBMX,
Dex or both IBMX C Dex (Fig. 5C). As expected, IBMX alone
substantially increased cAMP levels to a similar level at all time
points examined. In contrast, treatment with Dex alone had no
effect on cAMP levels at early time points, and a very minimal
effect with 4 h of treatment. Importantly, stimulation with both
IBMX and Dex did not significantly increase the level of intracel-
lular cAMP compared to IBMX alone at any time point. There-
fore, IBMX is mostly likely acting via cAMP while the effect of
Dex on CD24 is cAMP-independent.
Next we assessed if an increase in cAMP is sufficient to
increase CD24 mRNA expression by treating cells with increas-
ing concentrations of forskolin, which increases intracellular
cAMP levels via activation of adenylate
cyclase and not phosphodiesterase inhibi-
tion.24 We found that treatment with all
concentrations of forskolin tested, but not
the inactive forskolin analog (1,9-dideoxy-
forskolin) or DMSO alone, increased the
level of CD24 mRNA to a similar level to
that of IBMX C Dex treatment (Fig. 5D).
The increase in CD24 was maximal at all
doses of forskolin tested suggesting that reg-
ulation of CD24 expression by cAMP
requires a threshold of cAMP concentration
that is met at all concentrations of forskolin
tested.
Previous studies have shown that CD24
mRNA levels can be regulated by activating
transcription25,26 or by regulating mRNA
stability.27 To determine if the increase in
CD24 mRNA requires active transcription,
3T3-L1 cells were pre-treated with actino-
mycin D (ActD), an inhibitor of RNA syn-
thesis28 for 1 h followed by treatment with
IBMX C Dex for 6 h. Treatment with
ActD completely blocked the increase in
CD24 expression seen with IBMX C Dex
treatment (Fig. 6A), showing that the initial
increase in CD24 mRNA levels requires
activation of the transcriptional machinery.
Even though active transcription was
found to be necessary to increase CD24
mRNA levels initially, there is still the possi-
bility that maintenance of high levels are in
response to decreased mRNA degradation.
Therefore, to determine if active transcrip-
tion is also necessary to maintain CD24
mRNA levels, 3T3-L1 cells were first treated
with IBMX C Dex for 6 h to raise CD24
levels followed by treatment with ActD to
inhibit further transcription (Fig. 6B).
There was a substantial and significant
decrease in CD24 levels in the absence of active transcription,
indicating that transcription is also necessary for the maintenance
of CD24 transcript levels.
Activation of transcription factors can occur via increased
expression of a transcriptional activator or via post-translation
modification to a pre-existing transcriptional activator. To
determine which one of these possibilities is the case for CD24,
3T3-L1 cells were pre-treated with cycloheximide (CHX),
which blocks translational elongation29 for 1 h followed by
treatment with IBMX C Dex for 6 h. We found that addition
of CHX did not reduce the IBMX C Dex-mediated increase in
CD24 expression (Fig. 6C). We observed a significant increase
in CD24 expression following treatment with CHX alone,
which is consistent with the response of other early response
genes to CHX treatment.30,31 Therefore, the increase in CD24
mRNA expression does not require de novo protein synthesis
Figure 6. Active transcription, but not de novo protein synthesis, is necessary to induce CD24
expression in response to IBMX C Dex. A-C. Expression of CD24 mRNA was determined by RT-
qPCR and were normalized to the internal control Rplp0 and calculated relative to levels in cells
treated with DMSO (not shown). (A) Confluent 3T3-L1 cells were treated with actinomycin-D
(ActD) for 1 h to inhibit transcription, followed by IBMX C Dex (I/D) 6 h. n D 3-4, (B) Confluent
3T3-L1 cells were treated with I/D for 6 h followed by ActD for 6 h. Data are shown as log2 trans-
formed mean § s.e.m., n D 3, (C) Confluent 3T3-L1 cells treated with cyclohexamide (CHX) for
1 h, followed by I/D for 6 h. Data are shown as log2 transformed mean § s.e.m., n D 5. (D) 3T3-
L1 cells were transfected with pGL4.17 reporter vector, with or without the indicated CD24 pro-
moter, along with the pRL-SV40 transfection control vector. Cells were stimulated for 24 h as indi-
cated and promoter activity calculated as relative expression of Firefly/Renilla in response to I/D
stimulation compared to DMSO treated cells. Data are mean § s.e.m., n D 3.*P < 0.05.
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and is most likely due to activation of a pre-existing regulatory
protein.
Lastly, we analyzed the response of the CD24 promoter region
immediately upstream of the transcriptional start site (Fig. 6D).
We found IBMX C Dex treatment caused a significant increase
in promoter activity compared to the control treatment as mea-
sured by luciferase production. Together, these data demonstrate
that IBMX C Dex induces transcription of CD24, most likely
through activation of a pre-existing transcription factor binding
to the CD24 promoter.
Increased CD24 expression is necessary for mature adipocyte
formation
The dynamic increase in CD24 early during adipogenesis sug-
gests that this increase in CD24 may contribute to the regulation
of adipogenesis. To determine if CD24 regulates adipogenesis,
we transfected proliferating 3T3-L1 pre-adipocytes with siRNA
to block the IBMX C Dex-induced increase in CD24 expression
(Fig. 7). We confirmed that CD24 mRNA levels were decreased
in response to CD24 siRNA at all 3 stages examined (confluent,
initiation, and maturity), with the knock-down of mRNA
showing statistical significance at initiation and with a trend
toward significance at maturity (Fig. 7A). Analysis of CD24 pro-
tein surface expression revealed a significant decrease in the per-
centage of cells expressing CD24 at both confluent and initiation
stages (Fig. 7B). Furthermore, as measured by relative MFI,
siRNA treatment significantly reduced the level of surface expres-
sion by 32 § 7% (P < 0.01) in confluent cells and 54 § 4%
(P < 0.001) 20 h after addition of IBMX C Dex. Overall, cells
that retained CD24 expression did so at a lower level (Fig. 7B).
Therefore, the dynamic increase in CD24 expression in response
to IBMX C Dex was severely and significantly blunted at both
the mRNA and protein levels.
We found that this reduced expression of CD24 substantially
reduced the development of mature adipocytes as assessed visu-
ally by overall lipid accumulation at maturity (Fig. 7C), which
was revealed to be statistically significant by quantification of Oil
Red O staining (Fig. 7D).
We then analyzed the effect of blunting the increase in CD24
on the changes in adipogenic gene expression (Fig. 8). We found
that expression of the late adipogenic genes Pparg, Cebpa, and
adiponectin were substantially and significantly decreased, but
Figure 7. An increase in CD24 mRNA expression is necessary for adipocyte differentiation. (A) Proliferating 3T3-L1 cells were transfected with scrambled
control siRNA or CD24 siRNA, and then induced to undergo adipogenesis as described for Figure 1. The mRNA expression of CD24 was determined by
RT-qPCR when cells were confluent (Conf), 6 h after addition of IBMX C Dex (Init) and 5 days after addition of insulin (Mat). CD24 expression was normal-
ized to the internal control gene Rplp0 and relative expression levels are shown with respect to levels in confluent control siRNA cells. Data shown as log2
transformed mean § s.e.m., n D 7. (B) Surface CD24 protein expression was determined by flow cytometry in confluent cells (confl), and 20 h after addi-
tion of IBMX C Dex (I-20 h). Percent CD24-positive cells are shown as mean § s.e.m., n D 3. (C) Intracellular lipid was stained with Oil Red O and cells
imaged. Scale bar D 200 mm. One representative field of view of 5 independent experiments is shown. (D) Quantification of Oil Red O shown as
mean § s.e.m., n D 4. *P < 0.05, **P < 0.01.
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not completely abrogated, at maturity in the CD24 knock-down
cells. In addition, Cebpa expression at initiation was reduced to
below the amount expressed in a confluent cells, to a degree that
approached statistical significance. Surprisingly, the expression of
Pref1 was found to be significantly increased at maturity with
CD24 knock-down. Together, these data suggest that overall
gene expression associated with adipogenic development was
altered. Thus, we can conclude that the increase in CD24 expres-
sion that normally occurs early during adipogenesis in response
to IBMX C Dex treatment is necessary for maximum differentia-
tion but that a reduced level of adipocyte gene expression induc-
tion can still occur.
Discussion
Here, we show for the first time that the expression of CD24
is dynamically regulated at the mRNA and protein levels during
adipogenesis in the 3T3-L1 pre-adipocyte cell line and in pri-
mary pre-adipocytes. This increase in CD24 mRNA is driven by
activation of transcription from the CD24 promoter and is
dependent on activation of a pre-existing transcriptional regula-
tory protein. Furthermore, increasing intracellular cAMP or Dex
treatment was sufficient to increase CD24 mRNA levels, with
these factors acting additively to cause the maximal increase in
CD24 mRNA expression. Lastly, we demonstrate that this
dynamic upregulation of CD24 is necessary
for the formation of mature adipocytes and
to allow maximal expression of mature adi-
pogenic genes, as well as downregulation of
the pre-adipocyte gene Pref1.
We observed that the increase in CD24
expression preceded the increased expres-
sion of known adipogenic genes Pparg,
Cebpa and adiponectin in both 3T3-L1
cells and primary cells. In addition, the
increase in CD24 expression preceded
the decrease in Pref1 expression. Therefore,
the initial regulation of CD24 expression
occurs in a very early stage in the differenti-
ation process. The increase in surface
CD24 protein was delayed compared to
the upregulation of either total protein or
mRNA. This delay is consistent with the
requirement for transcription followed by
subsequent post-transcriptional modifica-
tions of CD24, including addition of the
GPI-anchor and glycosylations known to
be present on surface CD24.20
We observed a rapid increase, then
decrease, in CD24 expression in both 3T3-
L1 and siSVF cells while eSVF cells had a
rapid increase but delayed, gradual decrease
in expression. In addition to differences in
CD24 regulation, we also observed several
differences in the regulation of adipogenic
gene expression between 3T3-L1 pre-adipocytes and those iso-
lated from siSVF and eSVF. We observed that eSVF pre-adipo-
cytes show a similar trend as the 3T3-L1 cell line with respect to
the downregulation of Pref1, which are consistent with published
data.11,32 In contrast, siSVF had a significant increase in Pref1
expression, which is maintained once cells reach maturity. It is
unclear why Pref1 expression increases in siSVF cultures in corre-
lation with the increase in mature adipogenic genes since Pref1 is
known to inhibit adipogenesis.11,32 However, this may be due to
the fact that the cells isolated from WAT depots are heteroge-
neous and therefore contain cells that are at various stages of
commitment along the adipocyte lineage. Subcutaneous WAT
possess more adipogenic progenitors than visceral WAT
depots,33-35 which is consistent with our observed increase in the
expression of late adipogenic markers in siSVF compared to
eSVF. Therefore, an increase in ADSC in siSVF could result in
an increase and then decrease in Pref1 expression as these cells
commit to the adipocyte lineage.
All 3 types of cells showed the expected increase in PPARg
expression, however, cells from siSVF displayed an earlier and
more substantial increase than either of the other cell types, simi-
lar to previous reports.33,35 Unexpectedly, in eSVF cells we only
observed a modest increase in adiponectin expression and no
increase in Cebpa expression, while both of these genes showed a
robust regulation in both 3T3-L1 and siSVF cells. The loss of
Pref1, absence of Cebpa increase, and maintenance of CD24 in
Figure 8. An increase in CD24 mRNA expression is necessary to increase mature adipocyte gene
expression and decrease Pref-1 expression. The mRNA expression of Pref1, Pparg, Cebpa, and Adi-
ponectin was determined from cells that had been transfected with scrambled control siRNA or
CD24 siRNA as for Figure 7. mRNA levels were determined by RT-qPCR when cells were confluent
(Conf), 6 h after addition of IBMX C Dex (Init) and 5 days after addition of insulin (Mat) followed
by normalization to the internal control gene Rplp0. Relative expression levels are shown
with respect to levels in confluent cells. Data shown as log2 transformed mean § s.e.m., n D 4.
*P < 0.05, **P < 0.01.
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eSVF suggest there may be an arrest of cells in an earlier stage of
differentiation that prevents or delays the differentiation of these
cells, and therefore impedes the acquisition of PPARg and adipo-
nectin. It is important to note, that the mature cells were sampled
only 5 days after addition of insulin, and it has been consistently
reported that pre-adipocytes can continue to differentiate for up
to 10 days after addition of insulin (e.g.16,33,36). Therefore, it is
likely we are observing a delay in differentiation of the eSVF cul-
tures compared to siSVF and 3T3-L1 pre-adipocytes. Neverthe-
less, together these data support earlier conclusions that
subcutaneous pre-adipocytes have more differentiation potential
than visceral pre-adipocytes and that this difference is maintained
at the gene expression level.2 Moreover, with the exception of
Pref1, 3T3-L1 cells appear to model the changes in gene expres-
sion of siSVF more closely than eSVF.
We found that increasing cAMP, by addition of IBMX or
Forskolin, or the addition of Dex were sufficient to increase
CD24 expression with these messengers acting additively to max-
imal increase expression during initiation of adipogenesis. The
primary role of IBMX, identified thus far, appears to be to
activate the CREB transcription factor, which in turn activates
C/EBPb to drive Cebpa and PPARg expression.13 Dex, on the
other hand, activates the GR and appears to prime pre-adipocytes
to undergo further differentiation and acts either prior to, or
simultaneously with, the actions of IBMX.16 However, 3T3-L1
cells can be directed toward the osteoblastic lineage under specific
conditions,37 a process which also requires Dex but has no
reported association with CD24 expression. Therefore, the addi-
tive effect of IBMX and Dex on CD24 expression may be to
increase CD24 expression above an undefined threshold that
contributes to adipocyte lineage commitment and subsequent
differentiation.
Here, we demonstrate that active transcription is necessary for
both the initial increase and to maintain high levels of CD24
mRNA levels in response to IBMX C Dex. Furthermore,
although we found a partial increase in CD24 mRNA with CHX
treatment alone, there was no reduction in IBMX C Dex-
induced increase in CD24 mRNA when protein synthesis was
inhibited by CHX treatment. Therefore, we can conclude that
protein synthesis is not necessary for the IBMX C Dex induced
transcription of CD24. Furthermore, the CD24 promoter region
was responsive to IBMX C Dex. These data suggest that activa-
tion of a pre-existing regulatory protein, most likely a transcrip-
tion factor, causes the increase in CD24 promoter activity
resulting in increased mRNA levels. There are several transcrip-
tion factors that can regulate CD24 expression, such NFAT5
(also known as TonEBP), which upregulates CD24 expression in
T-lymphocytes38 and TWIST1, which downregulates CD24
expression in breast cancer cells,25 however it is not clear which,
if either of these, regulates CD24 in response to IBMX C DEX.
Therefore, studies are currently ongoing to determine the precise
identity of the signaling molecules and transcription factor(s)
responsible for regulating CD24 expression.
Rodeheffer et al.18 established CD24 as a lineage marker for
pre-adipocytes that were able to reconstitute fat pads in vivo but
was dispensable for in vitro adipogenesis. As we show here, the
addition of IBMX C Dex increases the expression level of CD24
mRNA and protein in both 3T3-L1 cells and primary pre-adipo-
cytes. Furthermore, in primary pre-adipocytes we observed a
clear decrease in the CD24-negative population of cells upon
stimulation of adipogenesis in vitro, clearly demonstrating that
CD24-negative cells can acquire CD24 expression in vitro. This
dynamic regulation of CD24 has also been observed in cancer
cells.39 Therefore, the ability of sorted CD24-negative pre-adi-
poctyes to undergo adipogenesis in vitro can be explained by the
induction of CD24 expression in response to IBMX C Dex dur-
ing the in vitro adipogenesis assay. In contrast, in vivo acquisition
of CD24 after injection of sorted CD24-negative cells into A-
Zip mice may not have occurred in the absence of substantial
and local increases in, as of yet undefined, extracellular mediators
that can activate intracellular cAMP and GR.
The precise role of CD24 in regulating adipogenesis is not
clear. The dynamic increase in expression that occurred early dur-
ing differentiation with reduced expression by maturity in all 3
cell types suggests that CD24 is acting very early in the in vitro
differentiation process. Prevention of the early increase in expres-
sion by siRNA resulted in a severe reduction in overall adipogen-
esis as measured by lipid accumulation and a significant
reduction in the expression of mature adipogenic genes. This sug-
gests that either CD24 serves as a modifier for adipogenesis to
allow early changes in the differentiation process or that the low
levels of CD24 remaining in the siRNA-treated cells are sufficient
to allow for some maturation to occur. Future analysis to track
CD24 expression and subsequent differentiation at the single cell
level may reveal if the degree of increase in CD24 expression cor-
relates with adipogenesis in a cell autonomous manner, in order
to distinguish between these possibilities.
Work in developing B lymphocytes, has shown that CD24
controls the development of hematopeiotic cells past an early
checkpoint after B lymphocyte lineage commitment,40,41 with
CD24 demonstrating a similar rise and fall in expression over the
course of development.42 While the development of early adipo-
cytes has not been staged as finely as with B lymphocytes, the
similarity in expression profiles early during pre-adipocyte devel-
opment shown here and previously,19 as well as our finding that
the increase in CD24 expression is necessary for full differentia-
tion, suggests that CD24 may be playing a similar role in control-
ling a developmental checkpoint in pre-adipocyte commitment.
In summary, this work demonstrates that upregulation of
CD24 early during in vitro adipogenesis is a dynamic process
that actively promotes adipogenesis.
Materials and Methods
Cell lines, mice, and antibodies
The 3T3-L1 pre-adipocyte cell line was purchased from
ATCC (Manassas, VA, USA). Male C57BL/6 mice were pur-
chased from Charles River (Wilmington, MA, USA) and used
between 3 and 6 weeks of age. All animal use was approved the
Institutional Animal Use and Care Committee at Memorial
University.
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For protein gel blot, the antibodies (Abs) against CD24
(HIS50) and actin, and all secondary Abs were purchased from
Santa Cruz Biotechnology, Inc. For FACS analysis, biotinylated
anti-CD24 M1/69 antibody, streptavidin-FITC, anti-CD24
M1/69-APC and the isotype control Rat IgG-APC were pur-
chased from eBioscience, Inc.
Adipogenesis assay
All media and supplements were obtained from Life Technol-
ogies Co., unless otherwise indicated. 3T3-L1 cells were main-
tained in high-glucose DMEM supplemented with 10%
newborn calf serum and 1% antibiotic/antimycotic (DMEM/
NCS). 3T3-L1 cells were grown to confluency in 6-well (for
western blot or FACS analysis) or 12-well plates (for RNA analy-
sis), for 24 h prior to further manipulations.
To initiate adipogenesis, initiation media containing 0.5 mM
IBMX and 1 mM Dex (Millipore) in DMEM supplemented
with 10% FBS and 1% antibiotic/antimycotic (DMEM/FBS)
was added to the cells 48 h post-confluency. Media was replaced
with 10 mg/ml insulin (Sigma-Aldrich) in DMEM/FBS (pro-
gression media) 48 h later followed by replacement with
DMEM/FBS 48 h later. Cells were maintained in this media for
5 days, replacing the media every 2 days, at which time 40%
of cells were visually verified to have accumulated lipid droplets.
As negative controls for adipogenesis, 3T3-L1 cells were main-
tained in DMEM/NCS while untreated SVF cultures were main-
tained in DMEM/FBS.
Cells were lysed in Trizol (Life Technologies) for mRNA anal-
ysis, or RIPA lysis buffer (50 mM Tris-HCl, 0.02% w/v NaN3,
0.5% w/vsodium deoxycholate, 0.1% w/v SDS, 1% w/v NP-40,
150 mM NaCl, 1 mM PMSF, 1 mM sodium orthovanadate, 1
ug/ml aprotinin, 1£ HALT Phosphatase inhibitor [Thermo-
scientific]) for protein gel blot analysis.
When indicated, confluent cells were treated with the appro-
priate vehicle controls, forskolin or inactive forskolin (Millipore)
at various concentrations (1, 2.5, 10, or 20 mM), 20 mg/ml of
cycloheximide (CHX) (Millipore), or 1 mg/ml of actinomycin
(ActD) (Millipore) in DMEM/FBS.
Isolation and culture of primary pre-adipocytes
The stromal vascular fraction (SVF) was isolated from subcu-
taneous WAT from the inguinal hindlimb depot or visceral
WAT from the epididymal depot followed by digestion with
15 mg/ml Collagenase type 1 (Life Technologies) in Krebs-
Ringer-HEPES bicarbonate buffer (pH 7.4) containing 200 nM
adenosine and 1% bovine serum albumin (KRH) for 1 h at
37C [modified from43]. Tissue debris was removed by filtering
through a 100 mm mesh and the SVF collected by centrifuging
for 5 minutes at 400 £ g. The cells were washed 3 times in KRH
buffer, plated in DMEM/FBS, and then grown until confluency
in 10 cm plates (for FACS analysis) or in 6-well plates (for RNA
isolation).
RNA isolation, DNase treatment and cDNA synthesis
RNA was isolated using Trizol (Life Technologies), contami-
nating DNA removed with TURBO DNase (Life Technologies)
and cDNA synthesized from 500 ng of RNA using MMLV-RT
(Life Technologies), following the manufacturer’s protocols.
Quantitative reverse transcriptase PCR (RT-qPCR)
Fermentas Maxima SYBR Green qPCR Master Mix (2£)
(ThermoScientific) was used to carry out quantititative Reverse
Transcriptase PCR (RT-qPCR) from 10 ng of cDNA in an
Eppendorf Mastercycler instrument. Forward (F) and Reverse
(R) primer sequences, amplification efficiencies (E) and amplicon
sizes (S) used for each gene are as follows: Cd24 (E D 1.07, S D
109 bp), F: 50-ACT CAG GCC AGG AAA CGT CTC T-30, R:
50-AAC AGC CAA TTC GAG GTG GAC-30; Rplp0 (E D 1.03,
S D 101 bp), F: 50-TCA CTG TGC CAG CTC AGA AC-30, R:
50-AAT TTC AAT GGT GCC TCT GG-30; Pref1 (E D 1.01, S
D 182 bp), F: 50- CCC CCT TCG TGG TCC GCA AC-30, R:
50-GGT GGG TCG CAT TCA GCC CC-30; Cebpa (E D 1.00,
S D 127 bp), F: 50-TGG ACA AGA ACA GCA ACG AG-30, R:
50-TCA CTG GTC AAC TCC AGC AC-30; Pparg (E D 1.00, S
D 145 bp), F: 50-TGT TAT GGG TGA AAC TCT GGG-30, R:
50-AGA GCT GAT TCC GAA GTT GG-30;
Adipoq (E D 1.00, S D 192 bp), F: 50-GTT GCA AGC TCT
CCT GTT CC-30, R: 50-TCT CCA GGA GTG CCA TCT
CT-30. Ct values were analyzed for relative quantity after 40
cycles according to the equation described by Pfaffl.44 All primer
sets were validated and primer efficiencies determined according
to the MIQE guidelines.45
Western blot
Protein concentration was determined using the Bicincho-
ninic Acid (BCA) Protein Assay Reagent (ThermoScientific)
according to the manufacturer’s protocol and 20 mg of protein
was run on a 10% SDS-PAGE gel followed by transfer to nitro-
cellulose membranes. Antibodies were diluted in TBSTC 5%
skim milk as follows: CD24 (HIS50) 1:500, actin 1:2000. goat-
anti-rabbit IgG-HRP 1:2000, and goat-anti-mouse IgM-HRP
1:2000. Immobilon Western Chemiluminescent HRP Substrate
(Millipore) was used for signal detection. Images were acquired
using an AlphaImager Gel Documentation system with Fluo-
rChem HD2 software, version 3.4.0. Image manipulation was
limited to adjustments to brightness and contrast of the entire
image.
FACS analysis
Cells were recovered by scraping into cold FACS buffer
(1.9 mM NaH2PO4, 8.4 mM Na2HPO4, 0.15 mM NaCl, pH
7.2 with 1% heat inactivated FBS) at the indicated stages of adi-
pogenesis. All following incubations were at 4C in the dark.
3T3-L1 cells were washed 3 times in FACS buffer followed by
incubation of 0.5 mg of APC-labeled M1/69 antibody or isotype
control per 1 £ 106 cells for 30 minutes. Cells from siSVF were
washed 3 times in FACS buffer followed by incubation with or
without 0.5 mg of biotinylated M1/69 antibody per 1£ 106 cells
for 30 minutes in the dark, then 3 washes in FACS buffer, fol-
lowed by a 30 min incubation with 0.5 mg Streptavidin-FITC
for 30 min. In both cases, following an additional 3 washes in
cold FACS buffer, cells were fixed at room temperature in
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100 ml of IC Fixation buffer (eBioscience) for 20 minutes and
then diluted with 500 ml of FACS buffer and stored at 4C in
the dark until run on a BD FACSCalibur using Cell Quest Pro
software. Data were analyzed by FlowJo v10 (TreeStar Inc.).
cAMP analysis
3T3-L1 cells were lysed in 1% Triton X-100 in 0.1 M HCl.
cAMP concentrations were determined using the direct cAMP
ELISA kit (ENZO Life Sciences, Inc.) following the man-
ufacturer’s instructions.
Luciferase reporter assay
The CD24 promoter, as defined by the location correspond-
ing to the transcription start site, was amplified with the GC-
RICH Primer system (Roche, Indianapolis, IN, USA) using the
following primers: Forward ¡688 to -666: 50- GTT GGA TGC
TCC CGG GTA TGG -30, Reverse C1 to ¡20: 50 – GGA
GCG CGG CCG GCC GGC GG -30 and then cloned into the
BglII and HindIII sites upstream of the luciferase gene in the
pGL4.17 reporter vector (Promega). All sequences were verified
by sequence analysis. Proliferating 3T3-L1 cells were transfected
with 0.5 mg of the pGL4.17 with or without the CD24 promoter
and 20 ng pRL-SV40 vector using Jetprime (Polyplus Transfec-
tion) according to the manufacturer’s protocol. After 24 h of
transfection, the media was replaced with fresh DMEM/NCS for
6 h followed by treatment with DMSO, or 0.5 mM IBMX and
0.1 mM Dex, in DMEM/FBS for 24 h. Cells were lysed with
1£ passive lysis buffer and assayed for Firefly and Renilla Lucif-
erase activities using the Dual-Luciferase reporter assay kit
(Promega) according to the manufacturer’s instructions.
siRNA knock down of CD24 and lipid staining in 3T3-L1
cells
3T3-L1 cells were transfected with 100 nmol of siRNA for
CD24 (MMC.RNAI.N009846.12.1, IDT, Coralville, Iowa) or
100 nmol of control scrambled siRNA (51-01-19-08, IDT)
using a combination of Jetprime (4 ml) and Interferin (2 ml)
(PolyPlus Transfection) according to the manufacturer’s protocol
for Jetprime. Mature adipocytes were stained with 0.36% Oil
Red O in 60% isopropanol, following the instructions from the
Adipogenesis Assay Kit (Millipore), 5 days after addition of insu-
lin. Images taken using the Axio PrimoVert inverted microscope
with an AxioCam HR Rev3 using AxioVision software v 4.8.2.0
(Carl Zeiss Microscopy). Image manipulation was limited to
adjustments to brightness and contrast of both images equally.
Extracted Oil Red O was quantified at 520 nm.
Statistic analysis
Statistical analysis was performed using a one-way ANOVA
followed by a Tukey post hoc test if significant, using R, version
3,46 when comparing more than 2 samples. If comparing 2 sam-
ples, the Student’s t-test was used (Excel, version 14.1.0). Differ-
ences were considered significant at P < 0.05.
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